Audrey Gabelle

List of Publications by Citations

143 papers	4,126 citations	34 h-index	60 g-index
162 ext. papers	5,215 ext. citations	5.4 avg, IF	4.89 L-index

#	Paper	IF	Citations
143	Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. *Lancet Neurology, The*, **2017**, 16, 377-389	24.1	379
142	A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas. *Stem Cells*, **2007**, 25, 961-73	5.8	276
141	APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. *PLoS Medicine*, **2017**, 14, e1002270	11.6	204
140	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. *Nature Medicine*, **2020**, 26, 398-407	50.5	160
139	Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia. *Brain*, **2006**, 129, 3051-65	11.2	132
138	SQSTM1 mutations in French patients with frontotemporal dementia or frontotemporal dementia with amyotrophic lateral sclerosis. *JAMA Neurology*, **2013**, 70, 1403-10	17.2	131
137	C9orf72 repeat expansions are a rare genetic cause of parkinsonism. *Brain*, **2013**, 136, 385-91	11.2	128
136	Memantine in behavioral variant frontotemporal dementia: negative results. *Journal of Alzheimer's Disease*, **2011**, 23, 749-59	4.3	97
135	The French series of autosomal dominant early onset Alzheimer's disease cases: mutation spectrum and cerebrospinal fluid biomarkers. *Journal of Alzheimer's Disease*, **2012**, 30, 847-56	4.3	94
134	Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls. *Neurobiology of Aging*, **2017**, 59, 220.e1-220.e9	5.6	83
133	Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification. *Alzheimer's Research and Therapy*, **2020**, 12, 26	9	80
132	Risk of Alzheimer's disease biological misdiagnosis linked to cerebrospinal collection tubes. *Journal of Alzheimer's Disease*, **2012**, 31, 13-20	4.3	79
131	Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies. *Journal of Alzheimer's Disease*, **2016**, 51, 1033-43	4.3	76
130	SORL1 rare variants: a major risk factor for familial early-onset Alzheimer's disease. *Molecular Psychiatry*, **2016**, 21, 831-6	15.1	71
129	Cerebrospinal fluid amyloid-β42/40 ratio in clinical setting of memory centers: a multicentric study. *Alzheimer's Research and Therapy*, **2015**, 7, 30	9	71
128	Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers. *Alzheimer's and Dementia*, **2018**, 14, 858-868	1.2	70
127	Clinical proteomics of the cerebrospinal fluid: Towards the discovery of new biomarkers. *Proteomics - Clinical Applications*, **2008**, 2, 428-36	3.1	69

#			
126	Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure Heterogeneity. *Journal of Proteome Research*, **2016**, 15, 667-76	5.6	66
125	Correlations between soluble forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid. *Brain Research*, **2010**, 1357, 175-83	3.7	64
124	Screening of dementia genes by whole-exome sequencing in early-onset Alzheimer disease: input and lessons. *European Journal of Human Genetics*, **2016**, 24, 710-6	5.3	61
123	Decreased sAPPβ, Aβ38, and Aβ40 cerebrospinal fluid levels in frontotemporal dementia. *Journal of Alzheimer's Disease*, **2011**, 26, 553-63	4.3	56
122	Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria. *Journal of Neurology*, **2012**, 259, 2429-33	5.5	55
121	Cerebrospinal fluid levels of orexin-A and histamine, and sleep profile within the Alzheimer process. *Neurobiology of Aging*, **2017**, 53, 59-66	5.6	53
120	Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting. *Alzheimer's and Dementia*, **2013**, 9, 406-13	1.2	51
119	Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. *Alzheimer's and Dementia*, **2014**, 10, S390-S394.e2	1.2	50
118	Seizures in dominantly inherited Alzheimer disease. *Neurology*, **2016**, 87, 912-9	6.5	49
117	Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study. *Journal of Neurology*, **2014**, 261, 144-51	5.5	45
116	Cerebrospinal fluid collection tubes: a critical issue for Alzheimer disease diagnosis. *Clinical Chemistry*, **2012**, 58, 787-9	5.5	44
115	Validation of AclarusDx a blood-based transcriptomic signature for the diagnosis of Alzheimer's disease. *Journal of Alzheimer's Disease*, **2012**, 32, 169-81	4.3	44
114	Pathogenic p62/SQSTM1 mutations impair energy metabolism through limitation of mitochondrial substrates. *Scientific Reports*, **2017**, 7, 1666	4.9	43
113	Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study. *Journal of Alzheimer's Disease*, **2013**, 34, 297-305	4.3	42
112	Can event-related potential predict the progression of mild cognitive impairment?. *Journal of Clinical Neurophysiology*, **2011**, 28, 625-32	2.2	40
111	Adherence to multidomain interventions for dementia prevention: Data from the FINGER and MAPT trials. *Alzheimer's and Dementia*, **2019**, 15, 729-741	1.2	34
110	Central Nervous System and Peripheral Inflammatory Processes in Alzheimer's Disease: Biomarker Profiling Approach. *Frontiers in Neurology*, **2015**, 6, 181	4.1	34
109	Hypocretin and brain β-amyloid peptide interactions in cognitive disorders and narcolepsy. *Frontiers in Aging Neuroscience*, **2014**, 6, 119	5.3	34

108	Alzheimer's Disease: Advances in Drug Development. *Journal of Alzheimer's Disease*, **2018**, 65, 3-13	4.3	32
107	Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLM Scale. *Frontiers in Aging Neuroscience*, **2018**, 10, 138	5.3	32
106	HIV Neuroinfection and Alzheimer's Disease: Similarities and Potential Links?. *Frontiers in Cellular Neuroscience*, **2018**, 12, 307	6.1	32
105	Orthostatic Hypotension and Risk of Incident Dementia: Results From a 12-Year Follow-Up of the Three-City Study Cohort. *Hypertension*, **2017**, 70, 44-49	8.5	31
104	A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles. *Alzheimer's Research and Therapy*, **2014**, 6, 38	9	31
103	From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid. *Scientific Reports*, **2016**, 6, 25162	4.9	29
102	Association of Long-Term Diet Quality with Hippocampal Volume: Longitudinal Cohort Study. *American Journal of Medicine*, **2018**, 131, 1372-1381.e4	2.4	28
101	A Complex Relationship Between Suicide, Dementia, and Amyloid: A Narrative Review. *Frontiers in Neuroscience*, **2018**, 12, 371	5.1	25
100	Antibody-free quantification of seven tau peptides in human CSF using targeted mass spectrometry. *Frontiers in Neuroscience*, **2015**, 9, 302	5.1	24
99	Sex-specific association between neighborhood characteristics and dementia: The Three-City cohort. *Alzheimer's and Dementia*, **2018**, 14, 473-482	1.2	24
98	SILK studies - capturing the turnover of proteins linked to neurodegenerative diseases. *Nature Reviews Neurology*, **2019**, 15, 419-427	15	22
97	Causative Mutations and Genetic Risk Factors in Sporadic Early Onset Alzheimer's Disease Before 51 Years. *Journal of Alzheimer's Disease*, **2019**, 71, 227-243	4.3	22
96	Prion replication occurs in endogenous adult neural stem cells and alters their neuronal fate: involvement of endogenous neural stem cells in prion diseases. *PLoS Pathogens*, **2013**, 9, e1003485	7.6	22
95	Quantitative detection of amyloid-β peptides by mass spectrometry: state of the art and clinical applications. *Clinical Chemistry and Laboratory Medicine*, **2015**, 53, 1483-93	5.9	21
94	Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer's disease at the prodromal stage. *Journal of Neurology, Neurosurgery and Psychiatry*, **2018**, 89, 467-475	5.5	19
93	Primary Progressive Aphasia in the Network of French Alzheimer Plan Memory Centers. *Journal of Alzheimer's Disease*, **2016**, 54, 1459-1471	4.3	19
92	Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation. *Journal of Alzheimer's Disease*, **2016**, 50, 759-764	4.3	19
91	Absolute quantification of 35 plasma biomarkers in human saliva using targeted MS. *Bioanalysis*, **2016**, 8, 43-53	2.1	18

No.	Reference		
90	Clinical measurement of Hepcidin-25 in human serum: Is quantitative mass spectrometry up to the job?. *EuPA Open Proteomics*, **2014**, 3, 60-67	0.1	18
89	Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort. *Alzheimer's Research and Therapy*, **2017**, 9, 67	9	18
88	Association between serum hepcidin level and restless legs syndrome. *Movement Disorders*, **2018**, 33, 618-627	7	17
87	Development of new quantitative mass spectrometry and semi-automatic isofocusing methods for the determination of Apolipoprotein E typing. *Clinica Chimica Acta*, **2016**, 454, 33-8	6.2	17
86	Plasma ß-amyloid 40 levels are positively associated with mortality risks in the elderly. *Alzheimer's and Dementia*, **2015**, 11, 672-80	1.2	16
85	Towards a routine application of Top-Down approaches for label-free discovery workflows. *Journal of Proteomics*, **2018**, 175, 12-26	3.9	16
84	Plasma amyloid-ß levels and prognosis in incident dementia cases of the 3-City Study. *Journal of Alzheimer's Disease*, **2013**, 33, 381-91	4.3	16
83	Red blood cell membrane omega-3 fatty acid levels and physical performance: Cross-sectional data from the MAPT study. *Clinical Nutrition*, **2018**, 37, 1141-1144	5.9	15
82	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study. *PLoS Medicine*, **2020**, 17, e1003289	11.6	15
81	Long-term exposure to ambient air pollution and risk of dementia: Results of the prospective Three-City Study. *Environment International*, **2021**, 148, 106376	12.9	15
80	Relationships between objectives sleep parameters and brain amyloid load in subjects at risk for Alzheimer's disease: the INSIGHT-preAD Study. *Sleep*, **2019**, 42,	1.1	14
79	Excessive Sleepiness and Longer Nighttime in Bed Increase the Risk of Cognitive Decline in Frail Elderly Subjects: The MAPT-Sleep Study. *Frontiers in Aging Neuroscience*, **2017**, 9, 312	5.3	14
78	Systemic delivery of siRNA down regulates brain prion protein and ameliorates neuropathology in prion disorder. *PLoS ONE*, **2014**, 9, e88797	3.7	14
77	The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases. *BMC Cancer*, **2019**, 19, 110	4.8	14
76	Are migraine and non-migrainous headache risk factors for stroke in the elderly? Findings from a 12-year cohort follow-up. *European Journal of Neurology*, **2016**, 23, 1463-70	6	13
75	Exacerbated CSF abnormalities in younger patients with Alzheimer's disease. *Neurobiology of Disease*, **2013**, 54, 486-91	7.5	13
74	Reduced brain amyloid burden in elderly patients with narcolepsy type 1. *Annals of Neurology*, **2019**, 85, 74-83	9.4	13
73	What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France. *BMJ Open*, **2019**, 9, e026380	3	12

No.	Reference	IF	Cit
72	Anxiety and 10-Year Risk of Incident Dementia-An Association Shaped by Depressive Symptoms: Results of the Prospective Three-City Study. *Frontiers in Neuroscience*, **2018**, 12, 248	5.1	12
71	Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Isolated Supratentorial Cortical Superficial Siderosis. *Journal of Alzheimer's Disease*, **2016**, 54, 1291-1295	4.3	12
70	Quantification of hepcidin-25 in human cerebrospinal fluid using LC-MS/MS. *Bioanalysis*, **2017**, 9, 337-347	2.1	11
69	Predicting dementia using socio-demographic characteristics and the Free and Cued Selective Reminding Test in the general population. *Alzheimer's Research and Therapy*, **2017**, 9, 21	9	11
68	Intake of Meat, Fish, Fruits, and Vegetables and Long-Term Risk of Dementia and Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2019**, 68, 711-722	4.3	11
67	Biomarkers of Alzheimer's disease: the present and the future. *Revue Neurologique*, **2013**, 169, 719-23	3	11
66	Autoantibody profiling on high-density protein microarrays for biomarker discovery in the cerebrospinal fluid. *Journal of Immunological Methods*, **2008**, 338, 75-8	2.5	10
65	Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals. *Alzheimer's Research and Therapy*, **2020**, 12, 123	9	10
64	Semantic loss marks early Alzheimer's disease-related neurodegeneration in older adults without dementia. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2020**, 12, e12066	5.2	10
63	Neural correlates of episodic memory in the Memento cohort. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2018**, 4, 224-233	6	10
62	Prospective Associations Between Diffusion Tensor Imaging Parameters and Frailty in Older Adults. *Journal of the American Geriatrics Society*, **2020**, 68, 1050-1055	5.6	9
61	Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. *International Journal of Geriatric Psychiatry*, **2021**, 36, 324-333	3.9	9
60	A Clinico-Radiological Study of Cerebral Amyloid Angiopathy-Related Inflammation. *Cerebrovascular Diseases*, **2019**, 48, 38-44	3.2	8
59	Influence of activity space on the association between neighborhood characteristics and dementia risk: results from the 3-City study cohort. *BMC Geriatrics*, **2019**, 19, 4	4.1	8
58	Can we rely only on ratios of cerebrospinal fluid biomarkers for AD biological diagnosis?. *Alzheimer's and Dementia*, **2015**, 11, 1125-6	1.2	8
57	Initial memory deficit profiles in patients with a cerebrospinal fluid Alzheimer's disease signature. *Journal of Alzheimer's Disease*, **2014**, 41, 1109-16	4.3	8
56	Late-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer's disease: Interest of cerebrospinal fluid biomarker ratios. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2015**, 1, 371-9	5.2	8
55	Amyloid imaging in Alzheimer's disease: a literature review. *Journal of Nutrition, Health and Aging*, **2014**, 18, 723-40	5.2	8

54	Tau hyperphosphorylation on T217 in cerebrospinal fluid is specifically associated to amyloid-β pathology		8
53	Stable Isotope Labeling by Amino acid in Vivo (SILAV): a new method to explore protein metabolism. *Rapid Communications in Mass Spectrometry*, **2015**, 29, 1917-25	2.2	7
52	Plasma Aβ and neurofilament light chain are associated with cognitive and physical function decline in non-dementia older adults. *Alzheimer's Research and Therapy*, **2020**, 12, 128	9	7
51	Absence of Relationship Between Self-Reported Sleep Measures and Amyloid Load in Elderly Subjects. *Frontiers in Neurology*, **2019**, 10, 989	4.1	6
50	Identification of multiple proteoforms biomarkers on clinical samples by routine Top-Down approaches. *Data in Brief*, **2018**, 18, 1013-1021	1.2	6
49	Time Orientation and 10 Years Risk of Dementia in Elderly Adults: The Three-City Study. *Journal of Alzheimer's Disease*, **2016**, 53, 1411-8	4.3	6
48	Defining Vitality: Associations of Three Operational Definitions of Vitality with Disability in Instrumental Activities of Daily Living and Frailty among Elderly Over a 3-Year Follow-Up (MAPT Study). *Journal of Nutrition, Health and Aging*, **2019**, 23, 386-392	5.2	6
47	Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aβ and Tau Proteins in Elderly Patients With Mild Cognitive Impairment. *Frontiers in Aging Neuroscience*, **2018**, 10, 297	5.3	6
46	Generation of induced pluripotent stem cells (IRMBi001-A) from an Alzheimer's disease patient carrying a G217D mutation in the PSEN1 gene. *Stem Cell Research*, **2019**, 34, 101381	1.6	5
45	Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia. *Journal of Alzheimer's Disease*, **2020**, 74, 903-911	4.3	5
44	Development and validation of dried matrix spot sampling for the quantitative determination of amyloid β peptides in cerebrospinal fluid. *Clinical Chemistry and Laboratory Medicine*, **2014**, 52, 649-55	5.9	5
43	Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers. *Current Alzheimer Research*, **2018**, 15, 691-700	3	5
42	Isolated parkinsonism is an atypical presentation of GRN and C9orf72 gene mutations. *Parkinsonism and Related Disorders*, **2020**, 80, 73-81	3.6	5
41	Primary Progressive Aphasia Associated With Mutations: New Insights Into the Nonamyloid Logopenic Variant. *Neurology*, **2021**, 97, e88-e102	6.5	5
40	Diabetes Mellitus and Cognition: Pathway Analysis in the MEMENTO Cohort. *Neurology*, **2021**, 97, e836-e848		5
39	Clinical relevance of brain atrophy subtypes categorization in memory clinics. *Alzheimer's and Dementia*, **2021**, 17, 641-652	1.2	5
38	Cognitive Event-Related Potential, an Early Diagnosis Biomarker in Frail Elderly Subjects: The ERP-MAPT-PLUS Ancillary Study. *Journal of Alzheimer's Disease*, **2017**, 58, 87-97	4.3	4
37	Prospective associations between physical activity levels and white matter integrity in older adults: results from the MAPT study. *Maturitas*, **2020**, 137, 24-29	5	4

36	Palmomental Reflex a Relevant Sign in Early Alzheimer's Disease Diagnosis?. *Journal of Alzheimer's Disease*, **2016**, 49, 1135-41	4.3	4
35	Neurodegenerative dementia and parkinsonism. *Journal of Nutrition, Health and Aging*, **2010**, 14, 37-44	5.2	4
34	Plasma neurofilament light chain is associated with cognitive decline in non-dementia older adults. *Scientific Reports*, **2021**, 11, 13394	4.9	4
33	Re: Prospective Associations between Diffusion Tensor Imaging Parameters and Frailty in Older Adults. *Journal of the American Geriatrics Society*, **2020**,	5.6	3
32	Associations Between Physical Activity, Blood-Based Biomarkers of Neurodegeneration, and Cognition in Healthy Older Adults: The MAPT Study. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2021**, 76, 1382-1390	6.4	3
31	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview.. *Alzheimer's and Dementia*, **2021**,	1.2	3
30	How to optimize the use of biobanks from population-based cohorts in aging research. *Biogerontology*, **2016**, 17, 221-7	4.5	2
29	Meal-related difficulties and weight loss in older people: Longitudinal data from MAPT study. *Clinical Nutrition*, **2020**, 39, 3483-3488	5.9	1
28	In Vivo Large-Scale Mapping of Protein Turnover in Human Cerebrospinal Fluid. *Analytical Chemistry*, **2019**, 91, 15500-15508	7.8	1
27	Analytical challenges related to the use of biomarker ratios for the biological diagnosis of Alzheimer's disease. *Clinical Chemistry and Laboratory Medicine*, **2015**, 53, e175-7	5.9	1
26	Plasma MCP-1 and changes on cognitive function in community-dwelling older adults.. *Alzheimer's Research and Therapy*, **2022**, 14, 5	9	1
25	Biological and Neuroimaging Markers as Predictors of 5-Year Incident Frailty in Older Adults: A Secondary Analysis of the MAPT Study. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2021**, 76, e361-e369	6.4	1
24	Investigating the association between cancer and the risk of dementia: Results from the Memento cohort. *Alzheimer's and Dementia*, **2021**, 17, 1415-1421	1.2	1
23	MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology. *Annals of Clinical and Translational Neurology*, **2021**, 8, 1817-1830	5.3	1
22	Investigating the combination of plasma amyloid-beta and geroscience biomarkers on the incidence of clinically meaningful cognitive decline in older adults.. *GeroScience*, **2022**, 1	8.9	1
21	Complaints of daytime sleepiness, insomnia, hypnotic use, and risk of dementia: a prospective cohort study in the elderly.. *Alzheimer's Research and Therapy*, **2022**, 14, 12	9	0
20	Subjective cognitive and non-cognitive complaints and brain MRI biomarkers in the MEMENTO cohort. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2020**, 12, e12051	5.2	0
19	Socioeconomic inequalities in dementia risk among a French population-based cohort: quantifying the role of cardiovascular health and vascular events. *European Journal of Epidemiology*, **2021**, 36, 1015-1023	12.1	0

18	Ready-meal consumption in older people: association with obesity and dietary intake. *Aging Clinical and Experimental Research*, **2019**, 31, 855-861	4.8	0
17	Five-Year Lower Extremity Function is Associated with White Matter Abnormality in Older Adults. *Journal of the American Geriatrics Society*, **2021**, 69, 995-1002	5.6	0
16	Commentary: Fatty acids and Alzheimer's disease: evidence on cognition and cortical β-amyloid from secondary analyses of the Multidomain Alzheimer Preventive Trial. *journal of prevention of Alzheimer's disease, The*, **2018**, 5, 168-170	3.8	0
15	Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles.. *Journal of Neural Transmission*, **2022**, 129, 231	4.3	0
14	Healthcare Costs Associated with Potentially Inappropriate Medication Prescribing Detected by Computer Algorithm Among Older Patients. *Drugs and Aging*, **2022**, 39, 367-375	4.7	0
13	Stable Isotope Labeling Kinetics in CNS Translational Medicine: Introduction to SILK Technology. *Handbook of Behavioral Neuroscience*, **2019**, 29, 173-190	0.7	
12	Sulcal morphology as cognitive decline predictor in older adults with memory complaints.. *Neurobiology of Aging*, **2022**, 113, 84-94	5.6	
11	Imagerie métabolique et moléculaire : l'exemple des maladies neurodégénératives. *Bulletin De L'Academie Nationale De Medecine*, **2018**, 202, 1511-1521	0.1	
10	Immunoassay and Mass Spectrometry Methods for Tau Protein Quantification in the Cerebrospinal Fluid. *Neuromethods*, **2021**, 71-85	0.4	
9	Cross-sectional and longitudinal interaction effects of physical activity and APOE-ε4 on white matter integrity in older adults: The MAPT study. *Maturitas*, **2021**, 152, 10-19	5	
8	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study **2020**, 17, e1003289		
7	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study **2020**, 17, e1003289		
6	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study **2020**, 17, e1003289		
5	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study **2020**, 17, e1003289		
4	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study **2020**, 17, e1003289		
3	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study **2020**, 17, e1003289		
2	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study **2020**, 17, e1003289		
1	Explaining the association between social and lifestyle factors and cognitive functions: a pathway analysis in the Memento cohort.. *Alzheimer's Research and Therapy*, **2022**, 14, 68	9	